Vascepa is a prescription medication used to treat high triglyceride levels in adults. It contains the active ingredient eicosapentaenoic acid (EPA), which is derived from fish oil. The drug was first approved by the FDA in 2012 [1]. The drug is manufactured by Amarin Corporation, and its patent was set to expire in 2030 [1]. However, Hikma Pharmaceuticals has accused Amarin of preventing generic manufacturers from accessing the active pharmaceutical ingredient (API) necessary to produce Vascepa [2]. Hikma claims that Amarin is keeping a "lock" on API suppliers, which is preventing the production of generic versions of Vascepa [2].

Despite this, Lixia, a Chinese pharmaceutical company, has announced that it has received approval to sell a generic version of Vascepa in China [3]. This suggests that generic versions of Vascepa may be effective in treating high triglyceride levels. However, it is important to note that the efficacy of a generic drug may vary depending on the manufacturer and the specific formulation of the drug.

In summary, while Hikma Pharmaceuticals has accused Amarin of preventing the production of generic versions of Vascepa by keeping a "lock" on API suppliers, Lixia has received approval to sell a generic version of Vascepa in China. It is important to note that the efficacy of a generic drug may vary depending on the manufacturer and the specific formulation of the drug.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://www.fiercepharma.com/pharma/hikma-pharmaceuticals-accuses-adversary-amarin-keeping-lock-api-suppliers-preventing-generic
[3] http://www.lyxia.com/vascepa-expands-the-european-union-and-china-market-allowing-epa-as-a-generic-drug/